PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Negative EBIT growth while CRVO is at 22.12%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-59.22%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-272.88%
Negative net income growth while CRVO stands at 22.57%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-252.38%
Negative EPS growth while CRVO is at 46.66%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-313.33%
Negative diluted EPS growth while CRVO is at 46.66%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
10.47%
Share reduction more than 1.5x CRVO's 45.14%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-20.54%
Reduced diluted shares while CRVO is at 45.14%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-64.88%
Negative OCF growth while CRVO is at 57.79%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-57.97%
Negative FCF growth while CRVO is at 57.79%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16444.97%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-31629.64%
Negative 5Y OCF/share CAGR while CRVO is at 79.17%. Joel Greenblatt would question the firm’s operational model or cost structure.
-47124.26%
Negative 3Y OCF/share CAGR while CRVO stands at 98.15%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-24144.03%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-61703.68%
Negative 5Y net income/share CAGR while CRVO is 82.27%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-67595.61%
Negative 3Y CAGR while CRVO is 96.69%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
1169.73%
Below 50% of CRVO's 2859.78%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
1236.68%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.44%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-50.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
88.49%
R&D dropping or stable vs. CRVO's 377.02%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
34.89%
SG&A growth well above CRVO's 54.43%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.